News | January 25, 2013

ACC Highlighted Late-Breaking Trials Announced

Latest clinical trial data will be presented at ACC.13 meeting in March

January 25, 2013 — The American College of Cardiology (ACC) has released the late-breaking clinical trials that will be highlighted as the cutting edge of cardiology at the ACC.13 annual meeting March 9-11 in San Francisco. 

 
Opening Showcase and Late-Breaking Clinical Trials?
Session 300, Saturday, March 9, 8–10 a.m., South, Esplanade Ballroom:
 
• Final Results of Randomized Trial of Left Atrial Appendage Closure Versus Warfarin for Stroke/Thromboembolic Prevention in Patients With Non-Valvular Atrial Fibrillation (PREVAIL)
 
• HPS2-THRIVE: Randomized Comparison Of Extended-Release (ER) Niacin/Laropiprant 2 g Daily Versus Placebo in 25,673 Patients At High Risk Of Occlusive Vascular Events
 
 
Late-Breaking Clinical Trials II: Interventional?
Session 301, Sunday, March 10, 8–9:30 a.m., South, Esplanade Ballroom:
 
• Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome
 
• A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis who are not Candidates for Surgery: PARTNER 2, Cohort B Outcomes
 
• One-year Outcome of a Trial Comparing Second Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the NOBORITM Biolimus-Eluting versus Xience/Promus Everolimus-Eluting Stent Trial (NEXT)
 
• Comparison of DK Crush Versus Culotte Stenting for Unprotected Distal Left Main Bifurcation Lesions: Results from a Multicenter, Randomized, Prospective DKCRUSH-III study
 
• The Main Results of the CHAMPION PHOENIX Trial — A Comparison of Efficacy and Safety of Cangrelor to Standard of Care in Patients Requiring Percutaneous Coronary Intervention (PCI)
 
 
Late-Breaking Clinical Trials III: Chronic CAD/Stable Ischemic Heart Disease and Acute Coronary Syndromes
?Session 302, Sunday, March 10, 10:45 a.m. — 12:15 p.m., South, Esplanade Ballroom:
 
• The STREAM Trial, Enoxaparin compared to Unfractionated Heparin in Myocardial Infarction Patients Undergoing PCI
 
• Early Administration of Eplerenone in Patients With Acute Myocardial Infarction Without Heart Failure: Results of the Randomized, Double-Blind, Placebo-Controlled REMINDER Trial
 
• Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial
 
• Randomized Comparison of High-Dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy
 
• Evaluation of  Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina: Results From the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Randomized Clinical Trial
 
 
Late-Breaking Clinical Trials IV: General Cardiology
?Session 303, Monday, March 11, 8–9:30 a.m., South, Esplanade Ballroom: 
 
• Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis
 
• A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery On-Site and Community Hospitals Without Cardiac Surgery On-Site
 
• The German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients (GOPCABE) Study
 
• CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 year
 
• PRAGUE-6 Trial: Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in Patients With EuroSCORE ?6
 
 
Late-Breaking Clinical Trials V: Heart Failure ?
Session 304, Monday, March 11, 10:45 a.m. – 12:15 p.m., South, Esplanade Ballroom: 
 
• The St Vincent’s Screening To Prevent Heart Failure Study: Impact of Natriuretic Peptide Guided Screening and Treatment on Long-Term Prevalence of Left Ventricular Dysfunction, Heart Failure and Cardiovascular Events
 
• Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients With Chronic Heart Failure and Reduced Ejection Fraction
 
• The ASTRONAUT Study: Aliskiren Trial On Acute Heart Failure Outcomes
 
• Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial
 
 
For more information:  accscientificsession.cardiosource.org
 

Related Content

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Overlay Init